12.02.2010 • News • Abbott • Mergers & Acquisitions (M&A) • portfolio

Abbott Gets Green Light for Solvay Deal

The European Commission gave Abbott the go ahead to buy Solvay's pharmaceutical business for $6.6 billion, with certain sales conditions. Because of concerns about competition, Abbott will be required to divest Solvay's cystic fibrosis testing business.

Abbott announced its intention to buy Solvay's pharma business unit in September - a move the company said would help expand its geographical footprint and its product pipeline. The buyout opens doors for Abbott in the emerging markets of Eastern Europe and Asia, as well as access to new areas, such as hormone therapies and vaccines.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature